Pembro With Radiation With or Without Olaparib

This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized prostate cancer.

Trial Details

NCT ID
NCT05568550
Phase
PHASE2
Sponsor
Zin W Myint
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Pembrolizumab
  • Olaparib
  • Androgen Deprivation Therapy
  • Radiation Therapy
Locations (sample)
  • Lexington, Kentucky, United States|37.98869,-84.47772
  • Salt Lake City, Utah, United States|40.76078,-111.89105

Key Eligibility Criteria

  • Male participants with histologically confirmed adenocarcinoma of the prostate
  • High-risk / very high-risk status per NCCN guidelines
  • ECOG performance status 0 to 1
  • Regional lymph nodes are allowed.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →